Treating CIRS follows a stepwise protocol that addresses the illness from the outside in: first removing the environmental trigger, then clearing accumulated biotoxins from the body, eradicating resistant nasal bacteria, and finally correcting the downstream immune and hormonal disruptions that keep inflammation cycling. The approach most documented in the medical literature is the Shoemaker Protocol, which has shown statistically significant improvements in both objective biomarkers and symptom resolution across multiple clinical studies.1PubMed Central. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment Because CIRS involves a dysregulated innate immune response rather than a single infection or toxin, treatment that skips steps or tackles them out of order tends to stall, which is one of the most common reasons people with this condition feel like nothing works.
Why the Sequence Matters
CIRS is not like a standard infection where you take antibiotics and recover. The underlying problem is that certain people’s immune systems cannot properly recognize and clear biotoxins, particularly those from water-damaged buildings, certain algae, or other environmental sources. Their immune system stays in a state of chronic activation, producing inflammatory markers long after the initial exposure. Treatment has to work through this chain in order: you cannot calm downstream inflammation if the body is still being flooded with new toxins, and you cannot eradicate certain bacteria if the immune system is still suppressed by ongoing biotoxin exposure.
The sequential nature of the protocol reflects how the disease process unfolds. Environmental exposure leads to biotoxin accumulation, which triggers immune dysregulation, which allows opportunistic organisms like resistant nasal bacteria to colonize, which further suppresses regulatory hormones. Reversing this cascade means working backward through those layers. Clinicians who treat CIRS consistently report that patients who try to jump ahead, treating nasal bacteria before clearing the environment for instance, end up with recurrent colonization and ongoing symptoms.
Step One: Get Out of the Exposure
No amount of medication will resolve CIRS if you are still breathing in the biotoxins that caused it. The most common trigger is a water-damaged building, where mold, bacteria, and their byproducts create a complex mixture of inflammatory compounds. Treatment begins with identifying and either remediating or leaving the problematic environment. This is often the hardest step practically and emotionally, but it is non-negotiable.
Sustainable recovery requires an integrated approach that treats the building not just as a backdrop but as an active component in the healing process.2Medical Research Archives. Built Environment as a Dangerous Ecosystem Professional environmental testing can help determine whether a building is safe. The HERTSMI-2 scoring system, which measures specific mold species in dust samples, is commonly used alongside endotoxin and beta-glucan testing to determine whether a space meets clearance thresholds. A building that scores above safe thresholds will undermine every subsequent treatment step.
For people who cannot move or afford full remediation immediately, reducing exposure through high-quality air filtration, removing porous materials like carpet and fabric furniture, and addressing moisture sources can help. But partial measures are not equivalent to full clearance, and clinicians generally find that patients in partially remediated environments recover more slowly and less completely than those who achieve full clearance or relocate.
Biotoxin Binding with Bile Acid Sequestrants
Once the external source of biotoxins is eliminated, the next priority is pulling stored biotoxins out of the body. Biotoxins recirculate through a process called enterohepatic recirculation: the liver dumps them into bile, the bile enters the gut, and the toxins get reabsorbed back into the bloodstream instead of being excreted. Breaking this cycle requires a binder that grabs the toxins in the gut before they can be reabsorbed.
The standard pharmaceutical binders used in CIRS treatment are cholestyramine and Welchol (colesevelam). Both are bile acid sequestrants originally approved for lowering cholesterol, used off-label for biotoxin binding. Cholestyramine is the more potent binder and is typically the first choice, while Welchol is better tolerated and often used for patients who cannot handle cholestyramine’s side effects, which commonly include constipation, bloating, and nausea.3Medical Research Archives. The CIRS Protocol: A Sequential, Evidence-Based Treatment for Biotoxin-Associated Chronic Inflammatory Response Syndrome Treatment with a binder generally continues for at least four weeks, though many patients require longer courses depending on their toxin burden and biomarker response.
An important practical note: these binders are non-specific and will also bind medications, vitamins, and nutrients. They need to be taken separately from other supplements and prescriptions, typically with at least a one-hour gap. Failing to space them properly can reduce the effectiveness of other treatments.
What About Natural Binders?
Many patients ask about alternatives like activated charcoal, bentonite clay, or chlorella. Research on modified bentonite formulations has shown promising adsorption of specific mycotoxins in laboratory conditions, with an optimized blend of bentonite, humic acid, and beta-glucan-mannan achieving removal rates above 90% for several aflatoxins and nearly 99% for deoxynivalenol under simulated gastrointestinal conditions.4Nature / Scientific Reports. Optimization of modified bentonite mycotoxin binders for enhanced adsorption efficiency under simulated gastric and intestinal conditions These results are from in-vitro testing, though, meaning they were measured in a lab setting that mimics the gut rather than in human patients. The clinical evidence for natural binders in CIRS specifically is thin compared to cholestyramine, which has been studied in this patient population for over two decades.
That said, some CIRS practitioners do incorporate natural binders as adjuncts, particularly for patients who cannot tolerate pharmaceutical options. Pediatric protocols have explored herbal medicine alternatives as well, with reported improvements in cognition, respiratory health, and gastrointestinal symptoms.5Medical Research Archives. Chronic Inflammatory Response Syndrome: Exploring Neuroimmune Pathology and Multisystem Framework for Differential Diagnosis in Pediatrics- Part 1 The key point is that any binder, pharmaceutical or natural, still requires the environmental exposure to be eliminated first.
Eradicating MARCoNS
One of the more unusual aspects of CIRS treatment involves the nose. About 80% of confirmed adult CIRS cases harbor a specific type of antibiotic-resistant bacteria in the nasal passages called Multiple Antibiotic Resistant Coagulase Negative Staphylococci, or MARCoNS. These bacteria form biofilms and produce compounds that further suppress already-low levels of regulatory hormones. In healthy people, this colonization is rare, found in only about 1-2% of controls.3Medical Research Archives. The CIRS Protocol: A Sequential, Evidence-Based Treatment for Biotoxin-Associated Chronic Inflammatory Response Syndrome
Detecting MARCoNS requires a specific nasal swab processed with a particular culture technique. Standard nasal swabs processed by a general lab will often miss it. The bacteria must show resistance to penicillin and at least one other class of antibiotics to qualify. Regular coagulase-negative staph without the antibiotic resistance is a normal skin colonizer that does not need treatment.
Eradication follows a specific preparation sequence. Before starting any nasal antimicrobial, the patient should already be out of the contaminated environment, have been on fish oil (typically around 4,200 mg daily) for at least 10 to 14 days to modulate immune function, and have completed at least four weeks of bile acid sequestrant therapy to reduce internal biotoxin reservoirs.3Medical Research Archives. The CIRS Protocol: A Sequential, Evidence-Based Treatment for Biotoxin-Associated Chronic Inflammatory Response Syndrome Attempting to kill MARCoNS while still in a contaminated building is the most common reason eradication fails. The bacteria simply recolonize because the immune environment that allowed them to flourish has not changed.
The most commonly used eradication tool is BEG spray, a compounded nasal spray containing mupirocin (an antibiotic), EDTA (which disrupts biofilms), and gentamicin (a second antibiotic). It is used two sprays per nostril three to four times daily for about eight weeks, after which a repeat nasal swab confirms whether eradication was successful. Consistency matters here: skipping doses allows the biofilm to re-establish.
Correcting Immune and Hormonal Markers
After the environment is clean, biotoxins are being cleared, and MARCoNS are eradicated, the protocol moves to correcting the specific immune and hormonal abnormalities that CIRS creates. This is where treatment becomes highly individualized, guided by blood work rather than symptoms alone. Common lab abnormalities in CIRS include elevated TGF-beta (a marker of tissue remodeling and fibrosis), elevated C4a (a complement activation marker), low vasoactive intestinal peptide (VIP), and low melanocyte-stimulating hormone (MSH).
A case report of a patient with ulcerative colitis and severe chronic fatigue demonstrated this pattern clearly: testing revealed a multisusceptible HLA haplotype along with markedly elevated TGF-beta and clinically undetectable VIP.6PubMed Central. Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures The hormonal collapse is not random; it reflects the immune system’s prolonged state of activation suppressing regulatory neuropeptides that normally keep inflammation in check.
VIP replacement therapy, delivered as a nasal spray, has been studied in patients who completed the earlier protocol steps but still had refractory symptoms. In an open-label trial, VIP nasal spray safely reduced symptoms to control levels, corrected inflammatory parameters, raised VIP and MSH levels, normalized elevated pulmonary artery systolic pressure during exercise within two months, and enhanced quality of life. These improvements held for follow-ups as long as 18 months, though VIP and MSH levels remained somewhat lower than in healthy controls.7Health. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings VIP is typically reserved for the end of the protocol because using it while biotoxin exposure or MARCoNS colonization is still present tends to produce poor or unsustained results.
The Role of Genetics in Who Gets Stuck
A frustrating reality for many CIRS patients is that people around them, family members in the same house, coworkers in the same office, often feel fine. The reason lies in genetic variation in the HLA (human leukocyte antigen) system, which governs how your immune system identifies and responds to foreign substances. Certain HLA-DR/DQ haplotypes are associated with an impaired ability to clear biotoxins, particularly mycotoxins from mold.8PubMed. HLA gene variations and mycotoxin toxicity: Four case reports People carrying these haplotypes are described as “poor eliminators” because their immune system does not properly tag these toxins for removal, allowing them to recirculate and trigger ongoing inflammation.
Research into the transcriptomic signatures of CIRS patients has found disruptions in genes involved in wound healing, adaptive immunity, and innate immunity, with the HLA-T cell receptor axis appearing particularly affected. This pattern overlaps with what is seen in many autoimmune conditions, suggesting that HLA haplotype sensitivity may be a core driver of why some people develop chronic illness after biotoxin exposure while others recover quickly.9PubMed Central. Transcriptomic signatures in whole blood of patients who acquire a chronic inflammatory response syndrome (CIRS) following an exposure to the marine toxin ciguatoxin
HLA testing does not change the treatment protocol itself, but it can be useful for setting expectations. Patients with multisusceptible haplotypes tend to require longer treatment courses, may need more aggressive environmental controls, and are more vulnerable to relapse if re-exposed. Knowing your haplotype can also validate the experience of being sicker than everyone else in the same environment, which, for a condition that is still poorly recognized by many physicians, carries real psychological value.
Screening and Monitoring Progress
Visual contrast sensitivity (VCS) testing is one of the earliest screening tools used in CIRS evaluation. It measures your ability to distinguish patterns at different contrast levels, a neurological function that biotoxin exposure tends to impair. A recent study comparing four different VCS testing methods found that the best-performing test achieved sensitivity ranging from 85% to 100% and specificity from 60% to 80% for identifying biotoxin-exposed individuals, while other commercial options showed high sensitivity but lower specificity, making them better at catching possible cases but worse at ruling out false positives.10PubMed Central. Assessment of visual contrast sensitivity in biotoxin-exposed individuals using four testing methods
VCS testing is inexpensive and quick, making it useful both as an initial screen and as a way to track improvement during treatment. However, it is not diagnostic on its own. A failed VCS test prompts further investigation with blood biomarkers like C4a, TGF-beta, MMP-9, VIP, MSH, and others. These labs serve a dual purpose: confirming the diagnosis and providing measurable targets that guide each treatment step. Clinicians track these markers throughout the protocol, moving to the next step only when specific biomarkers have normalized or meaningfully improved. This biomarker-driven approach is one of the reasons the protocol is sequential rather than cafeteria-style.
Adjunctive Therapies
The core CIRS protocol focuses on removing triggers and correcting specific biomarkers, but many patients explore additional therapies to support recovery, particularly for the neurological symptoms like brain fog, fatigue, and sensory disturbances that can be among the slowest to resolve.
Hyperbaric oxygen therapy (HBOT) has attracted interest for its effects on neuroinflammation. Research shows that HBOT promotes mitochondrial function, stimulates new nerve cell growth, enhances synapse formation, and reduces inflammatory markers like TNF-alpha and IL-6. These mechanisms translate to clinical benefits including improved cognitive function, better recovery from brain injury and post-concussion syndrome, and symptom reduction in conditions like fibromyalgia.11PubMed Central. Hyperbaric oxygen therapy as a neuromodulatory technique: a review of the recent evidence While HBOT has not been studied specifically in CIRS clinical trials, the overlap in inflammatory mechanisms and symptoms makes it a plausible supportive intervention, and some CIRS practitioners report that patients benefit from it as a complement to the core protocol.
Other commonly explored adjuncts include low-dose naltrexone for immune modulation, omega-3 fatty acids (already built into the protocol as preparation for MARCoNS eradication), limbic system retraining programs for the neurological sensitization that often accompanies chronic inflammation, and mast cell stabilizers for patients with overlapping mast cell activation. None of these replace the core steps, but they can address symptoms and mechanisms that the standard protocol does not directly target.
Children and CIRS
CIRS in children presents diagnostic and treatment challenges that differ from adults. Children may not articulate symptoms like brain fog or fatigue in ways that are easily recognized, and their symptoms often overlap with other developmental and behavioral conditions. Researchers have noted that treatment-resistant cases of developmental delay, speech and language problems, and behavioral issues may actually involve undiagnosed CIRS as a missing component.5Medical Research Archives. Chronic Inflammatory Response Syndrome: Exploring Neuroimmune Pathology and Multisystem Framework for Differential Diagnosis in Pediatrics- Part 1
The treatment principles remain the same for children: environmental clearance first, then biotoxin binding, then addressing immune dysregulation. However, medication dosing is adjusted for body weight, palatability of binders becomes a practical issue (cholestyramine has a gritty texture that many children refuse), and the treatment timeline may differ because children’s developing immune and nervous systems sometimes respond faster, but are also more vulnerable to disruption. Pediatric protocols have incorporated herbal alternatives to pharmaceutical binders, and clinical reports show improvements across cognition, motor skills, respiratory and gastrointestinal function, and speech and language when CIRS treatment is integrated with other interventions the child may already be receiving.
Common Pitfalls That Derail Treatment
Even patients who understand the protocol can stumble over practical challenges that undermine their progress. The most frequent pitfall, worth emphasizing because of how often it occurs, is attempting to treat while still exposed. A person living in a water-damaged home who starts cholestyramine and nasal sprays is fighting an uphill battle because new biotoxins are entering their system daily. Some patients remediate part of their home but miss hidden mold in HVAC systems, behind walls, or in belongings that absorbed moisture. Post-remediation environmental testing is essential, not optional.
Another common error is treating MARCoNS too early. Patients who read about MARCoNS and get a nasal spray prescribed before clearing their environment or completing an adequate course of binder therapy frequently see the bacteria return within weeks. The protocol’s sequential design exists specifically because each step creates the conditions that allow the next step to work. Skipping ahead feels proactive but usually extends the total treatment timeline.
Cross-contamination from belongings is easily overlooked. Porous items, including clothing, books, mattresses, upholstered furniture, and stuffed animals, can carry enough mold fragments and mycotoxins to sustain exposure even after a patient moves to a clean environment. Some CIRS patients find they need to replace soft goods rather than simply cleaning them, which adds financial and emotional burden on top of an already demanding process.
Finally, medication interactions with binders trip people up regularly. Cholestyramine and Welchol bind indiscriminately, meaning thyroid medication, birth control, antidepressants, and other prescriptions taken too close to the binder will be partially neutralized. Patients on multiple medications need careful scheduling to ensure each drug has time to absorb before the binder sweeps through the gut.
Finding a Practitioner
One of the most practical challenges with CIRS treatment is that most conventional physicians have little familiarity with the condition or its treatment protocol. CIRS is not yet part of standard medical school curricula, and patients frequently report being dismissed or misdiagnosed with conditions like fibromyalgia, chronic fatigue syndrome, depression, or anxiety before finding a provider who evaluates them for biotoxin illness. Certified CIRS practitioners typically complete specialized training in the Shoemaker Protocol and maintain access to the specific lab panels needed for diagnosis and monitoring. Functional medicine and integrative medicine doctors are more likely to be familiar with CIRS than conventional internists or primary care physicians, though this is changing slowly as the published evidence base grows.
When evaluating a potential provider, look for someone who orders the full panel of CIRS biomarkers rather than relying on symptoms alone, who insists on environmental testing and clearance before starting treatment, and who follows the stepwise protocol rather than jumping straight to anti-inflammatory supplements or IV therapies. A practitioner who skips the environmental assessment or the biotoxin-binding phase is missing the foundation that everything else depends on. Telemedicine has expanded access somewhat, since much of the monitoring can be done through lab work and VCS testing, though environmental assessment still requires local resources.